Overview
Vitreous hemorrhage leading to optic nerve sheath bleeding is a severe condition threatening vision, often resulting from trauma or proliferative diabetic retinopathy. Prompt management is crucial to prevent irreversible visual loss 1.Diagnosis
Clinical Presentation: Severe reduction in visual acuity, floaters, and potentially optic nerve sheath dilation on imaging 1.
Diagnostic Tests:
- Ophthalmologic Examination: Slit-lamp examination, fundoscopy 1.
- Imaging: B-scan ultrasonography or MRI to assess vitreous hemorrhage and optic nerve sheath involvement 1.Management
First-Line Treatments:
- Surgical Intervention: Pars plana vitrectomy for persistent bleeding 1.
Adjunctive Therapies:
- Recombinant Activated Factor VII (rFVIIa): Initial dose 60-140 μg/kg, followed by maintenance doses of 20-60 μg/kg every 8 hours for 3-5 days 1.Special Populations
Trauma and Diabetic Retinopathy: Management strategies similar, but late presentation may worsen outcomes 1.
No Specific Data: Limited information on pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Consider recombinant activated factor VII (rFVIIa) for patients with severe vitreous hemorrhage unresponsive to initial management, with an initial dose of 60-140 μg/kg followed by maintenance doses of 20-60 μg/kg every 8 hours for 3-5 days (Evidence: Weak) 1.
Early surgical intervention with pars plana vitrectomy should be considered for persistent vitreous hemorrhage to prevent further visual compromise (Evidence: Expert opinion) 1.
Prompt diagnosis and timely intervention are critical to improving visual outcomes; delayed treatment may lead to poorer results, especially in trauma cases (Evidence: Moderate) 1.References
1 Alameri A, Baker NS. Successful use of recombinant activated factor VII in the treatment of vitreous haemorrhage: a report of seven cases. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2005. link